麗珠醫藥(01513.HK)擬為下屬附屬公司提供融資擔保
格隆匯4月8日丨麗珠醫藥(01513.HK)發佈公告,2020年4月8日,公司召開了第九屆董事會第三十八次會議,審議通過了《關於公司授信融資暨為下屬附屬公司提供融資擔保的議案》,同意公司向中國工商銀行股份有限公司等銀行申請最高不超過人民幣110.3億元或等值外幣的授信融資。
本次公司為下屬附屬公司提供融資擔保總金額約為人民幣96.19億元,其中,對資產負債率為70%以上的附屬公司擔保總額為19.88億元,對資產負債率低於70%的附屬公司擔保總額為76.31億元。上述擔保總金額佔最近一期經審計歸屬於母公司股東淨資產(111.67億元)的比例約為86.14%,需提交公司股東大會審議批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.